A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitor.
Journal Information
Full Title: Br J Clin Pharmacol
Abbreviation: Br J Clin Pharmacol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"CONFLICT OF INTEREST J.A.B., J.B., M.S., P.K.M., P.E.S., W.A.F., G.K.W., J.C.B., D.F., H.C., S.H., B.D., J.J.O. and R.K.P. are employees of and hold stock in GlaxoSmithKline (GSK). E.J.B‐H. is an NHS employee and part‐time employee for GSK. P.W. is a complementary worker with GSK. S.D., L.E. and Y.C. are former employees of GSK, and Y.C. also holds stock in GSK."
Funding Disclosure
Evidence found in paper:
"Funding information GlaxoSmithKline, Stevenage, UK"
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025